Welcome

Pre-Open

RMi Pre-opening: Recoil, ricochet with a cold shiver

February 24, 2026

The cautious rebound follows a mild C&GT sector sell-off with uncertainty still bounding with multiple earnings releases.… and much more shoveling

Earnings: AxoGen (AXGN), Beam Therapeutics (BEAM) and Supernus Therapeutics (SUPN)

Pre-open Signals: I’m passing, too many factors; if you understand probabilities, the inevitable is easier to maneuver

Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.

Never leave retail investor uninformed … I say what others won’t, so you can KNOW what others can’t!

Out and About

RegMed Investors (RMi) Q4/25 and FY25 Cell and Gene Therapy Earnings

February 15, 2026

A scorecard of covered companies

Q4/25 and FY254 net losses or incomes correlated to EPS leanings of per share value, cash positions and “runways”, financials outcomes and correlation of "street" expectations - it's a reflection of this universe's investing "status"

I have written what I as an investor would want to know …

Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.

Closing Bell

RMi Closing Bell: Snow shoeing through Ai and cell and gene therapy sector blizzard

February 23, 2026

The upsized sector portfolio will get lower as the earnings “shovel” digs even deeper; now watch-out for share pricing heart attacks

As I wrote this a.m., “ … still hesitant to shovel the “additional levies” of 16-18 inches <or percentages> and it’s still coming”

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed! It’s not always time to buy or sell; but it is time to KNOW why!

Research Notes

RegMed Investors (RMi) Q4/25 and FY25 Cell and Gene Therapy Earnings

February 15, 2026

A scorecard of covered companies Q4/25 and FY254 net losses or incomes correlated to EPS leanings of per share value, cash positions and “runways”, financials outcomes and correlation of "street" expectations - it's a reflection of this universe's investing "status" I have written what I as an investor would want to know … Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.

RMi Finance Note: Sangamo Therapeutics (SGMO) Offering 35.19 M shares priced at $0.4719

February 4, 2026

SGMO continues to fall -$0.0168 or -4.31% to $0.37 Proceeds are estimated at $25 M SGMO closed <Monday> at $0.5679 and is trading at -$0.1413 or -24.74% to $0.44 Cantor and Wells Fargo Securities are acting as joint book-running managers for the offering. The offering consisting of 35,190,292 shares of its common stock and pre-funded warrants to purchase 17,787,033 shares of its common stock, together with accompanying warrants to purchase 52,977,325 shares of its common stock.

RMi Financing Note: AxoGen (AXGN) Completed an offering of 4 M shares at $31.00

January 25, 2026

AXGN closed +$0.83 or +2.59% to $32.83 with an aftermarket value of +$0.16 or +0.49% Having increased the deal from US$85 million to US$124 M, with the funds earmarked for debt repayment, working capital, and general corporate uses. The gross proceeds expected to be approximately $124 M (assuming no exercise of the underwriters’ option expecting to close on 1/23/26, subject to the satisfaction of customary closing conditions.

Research Notes

February 15, 2026 RegMed Investors (RMi) Q4/25 and FY25 Cell and Gene Therapy Earnings A scorecard of covered companies Q4/25 and FY254 net losses or incomes correlated to EPS leanings of per share value, cash positions and “runways”, financials outcomes and correlation of "street" expectations - it's a reflection of this universe's investing "status" I have written what I as an investor would want to know … Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment. February 4, 2026 RMi Finance Note: Sangamo Therapeutics (SGMO) Offering 35.19 M shares priced at $0.4719 SGMO continues to fall -$0.0168 or -4.31% to $0.37 Proceeds are estimated at $25 M SGMO closed <Monday> at $0.5679 and is trading at -$0.1413 or -24.74% to $0.44 Cantor and Wells Fargo Securities are acting as joint book-running managers for the offering. The offering consisting of 35,190,292 shares of its common stock and pre-funded warrants to purchase 17,787,033 shares of its common stock, together with accompanying warrants to purchase 52,977,325 shares of its common stock. January 25, 2026 RMi Financing Note: AxoGen (AXGN) Completed an offering of 4 M shares at $31.00 AXGN closed +$0.83 or +2.59% to $32.83 with an aftermarket value of +$0.16 or +0.49% Having increased the deal from US$85 million to US$124 M, with the funds earmarked for debt repayment, working capital, and general corporate uses. The gross proceeds expected to be approximately $124 M (assuming no exercise of the underwriters’ option expecting to close on 1/23/26, subject to the satisfaction of customary closing conditions. January 21, 2026 RMi Research Note: Capricor Therapeutics (CAPR) Provides Regulatory Update on Deramiocel BLA Another Opinion: Is FDA’s No-New-Trial Stance on Deramiocel Reshaping the Investment Case for Capricor Therapeutics (CAPR)? https://finance.yahoo.com/news/fda-no-trial-stance-deramiocel-111135647.html I am NOT the only DISSENTER! s Capricor Therapeutics (CAPR) Still Attractive After A 72% One Year Share Price Jump. https://finance.yahoo.com/news/capricor-therapeutics-capr-still-attractive-052444220.html FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review process. CAPR expects to submit updates to the BLA in February 2026 to support continued FDA review. As previously disclosed, CAPR provided topline results from its P3 HOPE-3 clinical study to the FDA in late 2025. Rejected for more data. For all my … <some say> … RANTINGS, I say TRUTH … timing will be everything until the FDA “speaks;” the higher CAPR rose from 12/2’s $6.36, the steeper the fall! STICKING to my CONVICTION that Capricor Therapeutics (CAPR) is overbought and whose valuation is disconnected from fundamentals. January 20, 2026 RMi Research Note: Harvard Apparatus GT (OTCQB:HRGN): A new financing attempt? Financing on Deck: Harvard Apparatus RT (OTCQB: HRGN (Notice of Exempt Offering of Securities); who or what US institution would invest in this “entity” OTCQB: HRGN (closed flat again Monday 1/20 after Friday, 1/16 $0.00 at $1.45) entered into Securities Purchase Agreements with Investors agreeing to purchase in a private placement an aggregate of 411,765 shares of common stock for the aggregate purchase price of approximately $700 K and a purchase price per share of $1.70. Closed flat $0.00 Friday at $1.45 after Thursday’s +$0.0270 after Wednesday's -$0.10 with 6,980 shares traded after Tuesday’s -$0.38 after Monday’s +$0.01 after Friday’s $0.00) Such a deal, next joke! Broke, no patient data in 4 years, questionable management, serious unpaid bills in hundreds of thousands to partners and employees past and present; even was sued and had to pay for a patient DEATH, usually a death knell foe any company! Guess who's providing the lipstick for this pig! WHO and WHAT is its owner ... a Beijing, China percentage (%) “owned”, financed and run company … with patterns of share pricing manipulation? Cash starved, NO clinical data after 5-year ago IND Accumulated deficit to date = $103.2 M in 12 years ... U.S. investors BEWARE, forewarned is forearmed?

Indication intelligence, analysis and sector perception

What's Happening Today

Earnings